Calina, DanielaHernandez, Antonio FHartung, ThomasEgorov, Alexey MIzotov, Boris NikolaevichNikolouzakis, Taxiarchis KonstantinosTsatsakis, AristidisVlachoyiannopoulos, Panayiotis GDocea, Anca Oana2023-02-092023-02-092021-08-28Calina D, Hernández AF, Hartung T, Egorov AM, Izotov BN, Nikolouzakis TK, et al. Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2. Life (Basel). 2021 Aug 31;11(9):907.2075-1729http://hdl.handle.net/10668/18569In the context of the current COVID-19 pandemic, traditional, complex and lengthy methods of vaccine development and production would not have been able to ensure proper management of this global public health crisis. Hence, a number of technologies have been developed for obtaining a vaccine quickly and ensuring a large scale production, such as mRNA-based vaccine platforms. The use of mRNA is not a new concept in vaccine development but has leveraged on previous knowledge and technology. The great number of human resources and capital investements for mRNA vaccine development, along with the experience gained from previous studies on infectious diseases, allowed COVID-19 mRNA vaccines to be developed, conditionally approved and commercialy available in less than one year, thanks to decades of basic research. This review critically presents and discusses the COVID-19 mRNA vaccine-induced immunity, and it summarizes the most common anaphylactic and autoimmune adverse effects that have been identified until now after massive vaccination campaigns.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/COVID-19 pandemiccoronavirusesmRNA vaccinespublic healthside effectsHumansCOVID-19 VaccinesmRNA VaccinesPublic HealthCOVID-19RNA, MessengerPandemicsVaccinesCommunicable DiseasesDrug-Related Side Effects and Adverse ReactionsIatrogenic DiseaseTechnologyWorkforceresearch article34575056open accessVacunas de ARNmVacunas contra la COVID-19Recursos humanos Salud PúblicaTecnologíaPandemiasEnfermedades transmisiblesEnfermedad iatrogénicaEfectos colaterales y reacciones adversas relacionados con medicamentosARN Mensajero10.3390/life11090907PMC8467884https://www.mdpi.com/2075-1729/11/9/907/pdf?version=1630402012https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467884/pdf